Cargando…
Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer’s disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective e...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181823/ https://www.ncbi.nlm.nih.gov/pubmed/35682822 http://dx.doi.org/10.3390/ijms23116143 |
_version_ | 1784723878950469632 |
---|---|
author | Gutiérrez, Irene L. Dello Russo, Cinzia Novellino, Fabiana Caso, Javier R. García-Bueno, Borja Leza, Juan C. Madrigal, José L. M. |
author_facet | Gutiérrez, Irene L. Dello Russo, Cinzia Novellino, Fabiana Caso, Javier R. García-Bueno, Borja Leza, Juan C. Madrigal, José L. M. |
author_sort | Gutiérrez, Irene L. |
collection | PubMed |
description | A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer’s disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective effects. Noradrenaline involvement in this disease was first proposed after finding deficits of noradrenergic neurons in the locus coeruleus from Alzheimer’s disease patients. Based on this, it has been hypothesized that the early loss of noradrenergic projections and the subsequent reduction of noradrenaline brain levels contribute to cognitive dysfunctions and the progression of neurodegeneration. Several studies have focused on analyzing the role of noradrenaline in the development and progression of Alzheimer’s disease. In this review we summarize some of the most relevant data describing the alterations of the noradrenergic system normally occurring in Alzheimer’s disease as well as experimental studies in which noradrenaline concentration was modified in order to further analyze how these alterations affect the behavior and viability of different nervous cells. The combination of the different studies here presented suggests that the maintenance of adequate noradrenaline levels in the central nervous system constitutes a key factor of the endogenous defense systems that help prevent or delay the development of Alzheimer’s disease. For this reason, the use of noradrenaline modulating drugs is proposed as an interesting alternative therapeutic option for Alzheimer’s disease. |
format | Online Article Text |
id | pubmed-9181823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91818232022-06-10 Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target Gutiérrez, Irene L. Dello Russo, Cinzia Novellino, Fabiana Caso, Javier R. García-Bueno, Borja Leza, Juan C. Madrigal, José L. M. Int J Mol Sci Review A growing body of evidence demonstrates the important role of the noradrenergic system in the pathogenesis of many neurodegenerative processes, especially Alzheimer’s disease, due to its ability to control glial activation and chemokine production resulting in anti-inflammatory and neuroprotective effects. Noradrenaline involvement in this disease was first proposed after finding deficits of noradrenergic neurons in the locus coeruleus from Alzheimer’s disease patients. Based on this, it has been hypothesized that the early loss of noradrenergic projections and the subsequent reduction of noradrenaline brain levels contribute to cognitive dysfunctions and the progression of neurodegeneration. Several studies have focused on analyzing the role of noradrenaline in the development and progression of Alzheimer’s disease. In this review we summarize some of the most relevant data describing the alterations of the noradrenergic system normally occurring in Alzheimer’s disease as well as experimental studies in which noradrenaline concentration was modified in order to further analyze how these alterations affect the behavior and viability of different nervous cells. The combination of the different studies here presented suggests that the maintenance of adequate noradrenaline levels in the central nervous system constitutes a key factor of the endogenous defense systems that help prevent or delay the development of Alzheimer’s disease. For this reason, the use of noradrenaline modulating drugs is proposed as an interesting alternative therapeutic option for Alzheimer’s disease. MDPI 2022-05-30 /pmc/articles/PMC9181823/ /pubmed/35682822 http://dx.doi.org/10.3390/ijms23116143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gutiérrez, Irene L. Dello Russo, Cinzia Novellino, Fabiana Caso, Javier R. García-Bueno, Borja Leza, Juan C. Madrigal, José L. M. Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target |
title | Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target |
title_full | Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target |
title_fullStr | Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target |
title_full_unstemmed | Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target |
title_short | Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target |
title_sort | noradrenaline in alzheimer’s disease: a new potential therapeutic target |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181823/ https://www.ncbi.nlm.nih.gov/pubmed/35682822 http://dx.doi.org/10.3390/ijms23116143 |
work_keys_str_mv | AT gutierrezirenel noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget AT dellorussocinzia noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget AT novellinofabiana noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget AT casojavierr noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget AT garciabuenoborja noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget AT lezajuanc noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget AT madrigaljoselm noradrenalineinalzheimersdiseaseanewpotentialtherapeutictarget |